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It is well documented (1-3) that parenteral injection of bacterial endotoxin can cause
hemorrhagic necrosis of established experimental tumors. The anti-tumor effect is rapid, and is
confined to the core of the tumor which darkens, separates, and eventually is sloughed off.
However, in spite of the dramatic destruction of the center of the tumor, it is only in a small
percentage ofcases that hemorrhagic necrosis is followed by the complete regression of the ring
of viable tumor tissue that remains. Therefore, in most cases, hemorrhagic necrosis does little
more than cause an apparent temporary halt in tumor growth.
Investigations of the anti-tumor effect of endotoxin go back to the end of the last
century when Coley and Bruns (4, 5) were describing spontaneous regressions of
certain types of tumors in humans after acute bacterial infections, or after deliberate
injections of bacterial toxins. However, in spite of an enthusiastic beginning, the use
of mixed bacterial toxins in the treatment of cancer soon fell from favor because of
inconsistent and unpredictable results. Indeed, we still are in no position to rationally
predict which experimental tumors will undergo complete regression in response to
endotoxin treatment. The knowledge that hemorrhagic necrosis is a common conse-
quence of endotoxin treatment, whereas regression is relatively rare, would indicate,
moreover, that tumor necrosis and tumor regression are mechanistically separate
events. This possibility is strongly suggested by results of a published study (6) which
shows that endotoxin-induced regression, but not hemorrhagic necrosis, is inhibited
by treatment with anti-thymocyte serum. This result was interpreted as meaning that
regression, but not hemorrhagic necrosis, is dependent on the expression ofan acquired
state of anti-tumor immunity.
The purpose of this paper is to provide additional evidence for hypothesizing that
endotoxin-induced tumor regression, as distinct from hemorrhagic necrosis, is depend-
ent on the expression of a state of T-cell-mediated anti-tumor immunity that is only
generated in response to immunogenic tumors. The paper which follows will provide
evidence to support the additional proposition that endotoxin-induced tumor regres-
sion will not occur until the tumor has grown to a large enough size to evoke the
generation of an adequate level of concomitant anti-tumor immunity.
Materials and Methods
Mice.
￿
Breeding nuclei ofA/J, BALB/c, and DBA/2 mice were purchased from The Jackson
Laboratory, Bar Harbor, Maine, and used for the production of parental strains and Fl hybrids
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accordingto established breeding techniques. Breeding was performed underbarrier sustained
conditions. The F1 hybrids employed were AB6F1 (A X C57B1/6)CB6F1 (BALB/c X
C57B1/6), and B6D2F1 (C57B1/6 X DBA/2) . Mice of either sex were employed when they
were between 8 and 12 wk of age. C3H and AKR strains were used forproducinganti-Thy-1 .2
serum.
Tumors.
￿
The SA-1 spindle cell sarcoma syngeneic in A/J mice, the Meth A fibrosarcoma
syngeneic in BALB/c, the CaD2 mammary carcinoma syngeneic in DBA/2, and the BP3
benzpyrene-induced fibrosarcoma syngeneic in C57B1/6 were studied. Experiments with each
tumor were performed with a single stock of biofrozen cells. In the case of the SA-1 and Meth
A tumors, large numbers of cells were grown in ascites form in the peritoneal cavities of a large
number of syngeneic mice. They were harvested after 7 days of growth in heparinized
phosphate-buffered saline (PBS),' washed twice in PBS, and resuspended for biofreezing at
107/ml in minimalessentialmedium (MEM) containing 20%fetalcalf serumand 20% dimethyl
sulfoxide. They were stored in small aliquots over liquid nitrogen. Before each experiment an
aliquot was thawed, washed in PBS, and the cells grown intraperitoneally for two passages in
semisyngeneic F1 hybrid mice before being harvested, washed, and resuspended at an appro-
priate concentration in PBS for initiating tumors.
The CaD2 carcinoma and BP3 fibrosarcoma were passaged subcutaneously by trocar. A
single cell suspension of tumor cells was obtained by digesting finely diced pieces of tumor in
PBS containing DNase, collagenase, and trypsin (Sigma Chemical, Co., St. Louis, Mo.) as
previously described (7). These cells were biofrozen in aliquots as described above. Before each
experiment an aliquot was thawed, washed in PBS, and used to seed in vitro cultures in large
plastic tissue cultureflasks containing Fisher's medium (Grand Island Biological, Grand Island,
N.Y.) with 10% fetal calf serum, 100 U penicillin, 0.25 ILg fungizone, and 100ittgstreptomycin
per ml. The cells were allowed to grow to the desired density at 37°C in an atmosphere of 5%
C02 in air. They were detached from the bottom of the vessels by treatment with 0.2% EDTA
and 2% trypsin in Ca++- and Mg++-free PBS, washed, and resuspended at an appropriate
concentration in PBS for implantation into mice.
Tumor cells were always injected in a 0.05 ml vol of PBS with a 30 gauge needle. A great
deal of care was taken with injections. Primary tumors were implanted intradermally on the
ventral surface of the abdominal region, whilechallenge tumors were implantedsubcutaneously
in theright-hind footpad. The growth of primary tumors was monitoredby measuring changes
in tumor weight against time. The growth of challenge tumors was measured with dial calipers
as increases in the dorsoventral thicknessof the footpad as described previously (8).
Endotoxin.
￿
Salmonella enteritidis lipopolysaccharide B, lot no. 628857 from Difco Laboratories,
Detroit, Mich. was used for all experiments. It was suspended in sterile PBS at a concentration
of 1 mg/ml, aliquoted, and stored at -20°C.
T-Cell-Deficient Mice.
￿
Mice were rendered T-cell-deficient (THXB) as adults by thymec-
tomy, followed 7 days later by lethal (900 rads) whole-body gamma-irradiation delivered from
a cesium-137 irradiator at a midphantom dose rate of 35.5 rads/min. They were infused
intravenously immediately after irradiation with 2 X 106 syngeneic bone marrow cells and
employed in experiments 4-6 wk later. Sham-thymectomized mice treated in the same way
(XB) served as controls for the effect of irradiation.
Endotoxin-Induced Regression. Testing the susceptibility of tumors to endotoxin involved
initiating primary intradermal tumors with 106 or 2 X 106 tumorcells, allowing the tumors to
grow for 7 days, and then injecting the mice intravenously with 50 ltg ofendotoxin in a 0.2 ml
vol. Large numbers of mice were used, and the populations sampled against time for changes
in tumor weight. This involved excising and weighing the tumors from five mice at the time
intervals indicated. In contrast to published results of others (6), it was not possible to use
changes in tumordiameter to measureendotoxin-induced tumorregression, becausethetumors
regressed from the inside out.
Adoptive Transfer ofAnti-Tumor Immunity.
￿
Spleen cells from mice whose tumors had regressed
under the influence of endotoxin were examined for their ability to adoptively immunize
normal syngeneic recipients against a tumor cell challenge. Spleens were taken 10 days after
complete regression, and the cells harvested from finely diced pieces of spleen by passing the
`Abbreviations used in this paper: BCG, Bacillus Calmette-Guerin; MEM, minimal essential medium; PBS,
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pieces through a 200-mesh stainless steel screen into PBS containing 1% heat-inactivated fetal
calf serum according to procedures already described (9) . The spleen cells were thoroughly
washed and infused intravenously via a lateral tail vein into normal recipients that were
challenged 1 h laterin a hind footpad with cells of the immunizing tumor. The growth of the
challenge implant was monitored against time with dial calipers.
Treatment with Anti-Thy 1.2 Serum.
￿
Anti-Thy-1 .2 serum was produced by immunizing AKR
mice with C3H thymocytes. The specificity of the antiserum was tested by absorption with
brain tissue as described previously (10) . Its ability to abrogate the capacity of spleen cells to
transfer anti-tumor immunity was tested by treating the spleen cells at 5 x 10 /ml in a 1 :5
dilution of it for 20 min at 4°C. This was followed by a 30-min incubation in agarose-absorbed
guinea pig serum (11) at a dilution of 1 :5 in PBS. The cells were then washed in PBS and
resuspended for intravenous infusion.
Results
Susceptible and Nonsusceptible Tumors.
￿
The effect of a single intravenous injection of
50 Itg ofendotoxin on the growth of four different syngeneic murine tumors initiated
7 days earlier is shown in Fig. 1 . It can be seen that the SA-1 and Meth A tumors
completely regressed in all cases, whereas growth of the CaD2 and BP3 tumors was
hardly affected. Observation of mice for a period of 6 mo after tumor regression
revealed that the overall frequency of reemergence of tumors was less than 10%. This
conclusion is based on the results of several additional experiments, as well as on
results obtained with groups of 50 mice in which tumor regression and regrowth were
assessed visually. When regrowth of tumors did occur, it usually began within 10 days
of complete regression. It should be pointed out, moreover, that although endotoxin
caused complete regression ofall primary SA-1 tumors, a small percentage of animals
eventually succumbed to metastatic disease.
An additional observation was, that although endotoxin caused regression of only
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￿
The effect of intravenous administration of 50 ug of endotoxin (arrows) on four different
tumors initiated intradermally 7 days previously in semisyngeneic mice. All four tumors showed
hemorrhagic necrosis, but only the SA-1 and Meth A sarcomas subsequently underwent complete
regression. Means of five mice per time interval.M. J. BERENDT, R. J. NORTH, AND D. P. KIRSTEIN
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￿
Evidence that 7 day SA-1 and Meth A tumors showed the same pattern of endotoxin-
induced regression in syngeneic parental strain mice as in semisyngeneic F1 hybrids. Means of five
mice per time interval.
FIG . 3 .
￿
Endotoxin administration (arrows) failed to cause regression of 7 day Meth A tumors in
mice that were immunodepressed by 900 rads of gamma-irradiation given 24 h before tumor
implantation. Means of five mice per time interval.
two of the four tumors tested, hemorrhagic necrosis occurred in all four of them, and
was no greater in intensity in those tumors that underwent regression. In all cases, the
core of the tumor began darkening within a few hours, and the hemorrhagic reaction
increased in extensiveness over the next 48 h. It was the ring of viable tumor tissue
that remained, however, which eventually regressed in thecase of the SA-1 and Meth
A tumors, but which grew progressively to kill the hosts in the case of the BP3 and
CaD2 tumors.
Because most of the experiments to be reported in this paper were performed in F1
hybrid mice, it was necessaryto show that the same results areobtained with syngeneic
parental strains. That this was the case is shown in Fig. 2 where it can be seen that the
pattern ofendotoxin-induced regression of the SA-1 and Meth A tumors in syngeneic
mice was similar to that measured in semisyngeneic Fl hybrids. The CaD2 and BP3
tumors did not regress in parental strains.
Effect ofGamma-Irradiation on Endotoxin-Induced Regression.
￿
Fig. 3 shows that exposure
to 900 rads ofwhole-body gamma-irradiation 24 h before the intradermal inoculation
of Meth A cells, completely abrogated the ability of mice to regress tumors in response
to endotoxin therapy given on day 7 of tumor growth. In contrast, gamma-irradiation
had little or no effect on the degree of hemorrhagic necrosis. The same result was
obtained with the SA-1 sarcoma as evidenced by visual inspection. These findings
show, therefore, that a radiosensitive host component plays a role in endotoxin-
facilitated tumor regression, but not in hemorrhagic necrosis.
Failure of Regression to Occur in T-Cell-Deficient Mice.
￿
One interpretation of the1554 IMMUNOLOGICAL BASIS OF ENDOTOXIN-INDUCED TUMOR REGRESSION. I
Fic. 4.
￿
Endotoxin injection (arrow) failed to cause regression of 7 day SA-1 and Meth A tumors
in mice that were made T-cell deficient as adults by thymectomy and irradiation, and protected
with bone marrow cells (THXB). Regression occurred in irradiated, bone marrow-protected controls
(XB) in the same way as in normal controls (not shown). Means of five mice per time point.
preceding results is that endotoxin-induced tumor regression has an immunologic
basis. It was predicted, therefore, that endotoxin would not cause regression of
susceptible tumors growing on T-cell-deficient mice. Fig. 4 shows that this was indeed
the case, in that endotoxin failed to cause the regression of 7 day SA-1 and Meth A
tumors on mice made T-cell-deficient by thymectomy and gamma-irradiation, and
protected with bone marrow cells (THXB) . Here again, the degree of hemorrhagic
necrosis in the core of the tumors was not affected by the deficiency of T cells. It
seems clear, therefore, that hemorrhagic necrosis is not the cause by itself of tumor
regression.
The Generation of T-Cell-Mediated Anti-Tumor Immunity after Endotoxin-Induced Regres-
sion. The foregoing results suggest that T lymphocytes are involved in endotoxin-
induced tumor regression. It was expected, therefore, that endotoxin-induced tumor
regression would be associated both with the generation of a state of immunity to
tumor cell challenge, and with the possession of T cells capable of adoptively
immunizing normal recipients systemically against a tumor cell challenge.
Fig. 5 shows that mice whose SA-1 or Meth A tumors had regressed under the
influence of endotoxin were resistant to growth of an implant of cells of the same
tumor given subcutaneously 10 days later. The results in Fig. 6 show, in addition,
that the acquired resistance to tumor challenge was specific, in that mice whose MethM. J. BERENDT, R. J. NORTH, AND D. P. KIRSTEIN
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￿
Endotoxin-induced regression of 7 da~ intradermal SA-1 and Meth A tumors was followed
by a state of resistance to growth of a 5 X 10 tumor cell challenge implant given subcutaneously
in the right hind footpad. The mice were challenged 10 days after complete regression of the
primary tumor, Means of five mice per time interval.
FIG. 6.
￿
Evidence that the anti-tumor immunity generated by mice whose 7 day Meth A tumors
had regressed in response to endotoxin was specific. The strong resistant expressed against a 5 X 106
Meth A cell challenge implant was not expressed against 5 X 106 BP3 cells.
A tumors had regressed were not resistant to growth of 106 BP3 tumor cells. Another
significant finding was that this state of anti-tumor immunity was long lived, as
evidenced by resistance to a tumor challenge given 60 or 90 days after regression of
the primary tumor (Fig. 7),
Evidence that this state of tumor-specific immunity was mediated by sensitized T
cells is shown in Fig. 8 where it can be seen that it was associated with the presence
of cells in the spleen which could adoptively immunize normal recipients against a
tumor cell challenge, and that incubation of these spleen cells with anti-Thy-1.2
serum and complement completely ablated their protective capacity. The level of
adoptive immunity shown was transferred with 1 .5 X 108 spleen cells. It should be
pointed out that in these experiments the adoptive immunity was systemically
expressed, in that the spleen cells were infused intravenously and the tumor implant
given subcutaneously 1 h later.
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FIG. 7.
￿
Anti-tumor immunity generated after endotoxin-induced regression of the Meth A tumor
was long-lived, as evidenced by resistance to growth of an implant of 5 X 10 5 Meth A cells given 60
or 90 days after regression of the primary tumor. Means of five mice per time interval.
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FIG . 8 .
￿
Passive transfer of anti-tumor immunity (Meth A) to normal recipients with 1.5 X 10 8
spleen cells (1 spleen equivalent) from donor mice whose tumors had regressed 10 days previously
in response to endotoxin treatment. The protective capacity of the spleen cells was completely
ablated by incubating them in anti-Thy-1 .2 serum and complement, but not by incubating them
with normal AKR serum and complement (controls). An infusion of normal spleen cells is without
effect (not shown). Means of five mice per time interval.
It will be noted that there was an initial period during which the tumor challenge
implant apparently grew more in immunized and adoptively immunized mice than
it did in controls. It seems quite likely that this represented a delayed-type hypersen-
sitivity reaction to tumor associated antigens, and that an initial period o£ tumor
growth was required to supply enough antigen to elicit the reaction.
The Tumors that Regress in Response to EndotoxinareImmunogenic as Classically Defined.
￿
It
is logical to suggest on the basis of the foregoing results, that ofthe four tumors tested,
it is only the two that regress under the influence ofendotoxin which are immunogenic
as classifically defined. This prediction was tested by investigating the immunogenicity
of all four tumors by the classical method of determining whether surgical removal of
the primary tumor is followed by the acquisition of a state of immunity to a challenge
implant.
Fig. 9 shows the results of challenging mice subcutaneously with 106tumor cells 14
days after removal of their 7 day primary tumors. It can be seen that the only tumors
that showed immunogenicity by this method were the SA-1 and Meth A sarcomas:
those that completely regress in response to endotoxin therapy. The same result was
obtained when the challenge implants were given 7 and 21 days after tumor excision.
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FIG . 9 .
￿
Growth of a 106 subcutaneous challenge implant in control mice and in mice whose
primary tumors were excised 14 days previously . Only the SA-1 and Meth A sarcomas proved to be
immunogenic by this classical technique . Means offive mice per time interval .
Discussion
The results of this study are consistent with the hypothesis that endotoxin-induced
regression ofestablished murine tumors is immunologically mediated by an acquired
population of sensitized T cells which is generated only in response to tumors that are
immunogenic as classically defined . They show (a) that endotoxin will not induce
regression of susceptible tumors in mice that have been immunodepressed by whole-
body irradiation, or that have been made T-cell deficient by thymectomy and
irradiation, (b) that regression is followed by specific resistance to growth of a tumor
cell challenge, and with the presence of T cells that can passively transfer this
resistance to normal recipients, and (c) that the only tumors that regress are those
that are immunogenic as classically defined .
On the other hand, the dramatic phenomenon of hemorrhagic necrosis which
invariably precedes tumor regression, is not significantly diminished by whole-body
irradiation, or T-cell deficiency . Furthermore, it occurs with tumors that apparently
are nonimmunogenic and which do not regress . It is reasonable to suggest, therefore,
that endotoxin-induced hemorrhagic necrosis cannot be used as an indicator of the
therapeutic effectiveness of endotoxin, even though it may well be a prerequisite for
tumor regression to occur. It should be born in mind, moreover, that the cores of most
established solid tumors are extensively necrotic to begin with . Consequently, endo-
toxin may do little more than speed up necrosis and make the core of the tumor and
its immediate surroundings more visible. This would fit with the interpretations of
Stetson (12) who showed that endotoxin treatment results in a profound, though
temporary, reduction in the blood flow to solid tumors . Obviously, this would ensure
the rapid destruction of the already undernourished central region of the tumor .
A contradiction to this explanation could exist, however, in the fairly recent series
of publications of Carswell et al ., Green et al ., and Hoffman et al . (13-16) which
describe the liberation into circulation of a host factor, referred to as tumor necrosis1558 IMMUNOLOGICAL BASIS OF ENDOTOXIN-INDUCED TUMOR REGRESSION. I
factor, which follows the injection of endotoxin into Bacillus Calmette-Guerin (BCG)-
infected, or Corynebacterium parvum-treated mice. These authors showed that infusion of
serum containing tumor necrosis factor causes hemorrhagic necrosis and occasional
regression ofsusceptible tumors in recipient mice, and that the same serum is cytotoxic
for certain neoplastic and fetal cells in tissue culture. Indeed, it is mainly on the basis
of the latter property that the authors suggest that tumor necrosis factor is the
mediator of hemorrhagic necrosis and regression. However, most in vivo studies of
tumor necrosis factor have concentrated almost exclusively on its ability to cause
hemorrhagic necrosis, rather than on its ability to cause regression. It would be
interesting, therefore, to determine whether tumor necrosis factor causes the regression
of endotoxin-susceptible tumors in immunodepressed mice. If not, then it almost
certainly is not the direct mediator of the most important antitumor effect of
endotoxin: its capacity to cause a susceptible tumor to completely regress. It would
seem important to determine, in addition, whether tumor necrosis factor, besides
being liberated into the circulation of BCG- and C. parvum-treated mice, is also
liberated into the circulation of tumor-bearing mice themselves.
In spite of the evidence presented here for the T-cell mediation of endotoxin-
induced tumor regression, it is apparent from the literature that factors in addition to
tumor immunogenicity are involved in determining whether a tumor will regress in
response to endotoxin treatment. For example, tumor location and tumor size (17)
have been shown to be important. The reason why tumor size is important will be
discussed in the accompanying paper.
Summary
It was shown that although intravenous administration of bacterial endotoxin
caused extensive hemorrhagic necrosis of four different syngeneic murine tumors, only
two of these tumors subsequently underwent complete regression: the two that were
shown to be immunogenic as classically defined. An immunologic basis for endotoxin-
induced regression was further indicated by the additional findings that regression,
but not hemorrhagic necrosis, of the two immunogenic tumors failed to occur in mice
that were immunodepressed by whole-body gamma-irradiation, or that were made T-
cell deficient by thymectomy and irradiation. That endotoxin-induced regression is
T-cell mediated was suggested by the findings that tumor regression was followed by
a state of long-lived immunity to a tumor cell challenge implant, and with the
possession by the host of T cells that were capable of passively transferring this state
of immunity to normal recipients.
It is concluded that although parenteral injection of endotoxin causes hemorrhagic
necrosis of most solid murine tumors, it is only those tumors that are immunogenic
enough to evoke the generation of T-cell-mediated immunity which subsequently go
on to completely regress.
Receivedforpublication 18 August 1978.
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